» Articles » PMID: 21921041

Dysregulated MicroRNAs Affect Pathways and Targets of Biologic Relevance in Nasal-type Natural Killer/T-cell Lymphoma

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2011 Sep 17
PMID 21921041
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

We performed a comprehensive genome-wide miRNA expression profiling of extranodal nasal-type natural killer/T-cell lymphoma (NKTL) using formalin-fixed paraffin-embedded tissue (n = 30) and NK cell lines (n = 6) compared with normal NK cells, with the objective of understanding the pathogenetic role of miRNA deregulation in NKTL. Compared with normal NK cells, differentially expressed miRNAs in NKTL are predominantly down-regulated. Re-expression of down-regulated miRNAs, such as miR-101, miR-26a, miR26b, miR-28-5, and miR-363, reduced the growth of the NK cell line and modulated the expression of their predicted target genes, suggesting the potential functional role of the deregulated miRNAs in the oncogenesis of NKTL. Taken together, the predicted targets whose expression is inversely correlated with the expression of deregulated miRNA in NKTL are significantly enriched for genes involved in cell cycle-related, p53, and MAPK signaling pathways. We also performed immunohistochemical validation for selected target proteins and found overexpression of MUM1, BLIMP1, and STMN1 in NKTL, and notably, a corresponding increase in MYC expression. Because MYC is known to cause repression of miRNA expression, it is possible that MYC activation in NKTL may contribute to the suppression of the miRNAs regulating MUM1, BLIMP1, and STMN1.

Citing Articles

Predicting the Effect of miRNA on Gene Regulation to Foster Translational Multi-Omics Research-A Review on the Role of Super-Enhancers.

Das S, Rai S Noncoding RNA. 2024; 10(4).

PMID: 39195574 PMC: 11357235. DOI: 10.3390/ncrna10040045.


Non-coding RNAs as therapeutic targets in cancer and its clinical application.

Leng X, Zhang M, Xu Y, Wang J, Ding N, Yu Y J Pharm Anal. 2024; 14(7):100947.

PMID: 39149142 PMC: 11325817. DOI: 10.1016/j.jpha.2024.02.001.


Identification of PATL1 as a prognostic and immunotherapeutic predictive factor for nasal-type natural killer/T-cell lymphoma and head and neck squamous cell carcinoma.

Yang W, Peng C, Li Z, Yang W Heliyon. 2024; 10(11):e32158.

PMID: 38912458 PMC: 11190607. DOI: 10.1016/j.heliyon.2024.e32158.


Extranodal lymphoma: pathogenesis, diagnosis and treatment.

Yang H, Xun Y, Ke C, Tateishi K, You H Mol Biomed. 2023; 4(1):29.

PMID: 37718386 PMC: 10505605. DOI: 10.1186/s43556-023-00141-3.


Proteome analysis of CD5-positive diffuse large B cell lymphoma FFPE tissue reveals downregulation of DDX3X, DNAJB1, and B cell receptor signaling pathway proteins including BTK and Immunoglobulins.

Hiratsuka T, Ito S, Sakai R, Yokose T, Endo T, Daigo Y Clin Proteomics. 2023; 20(1):36.

PMID: 37705009 PMC: 10498596. DOI: 10.1186/s12014-023-09422-z.